Nautilus Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
October 31, 2023 at 08:05 am EDT
Share
Nautilus Biotechnology, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 15.88 million compared to USD 14.06 million a year ago. Basic loss per share from continuing operations was USD 0.13 compared to USD 0.11 a year ago.
For the nine months, net loss was USD 46.65 million compared to USD 44.52 million a year ago. Basic loss per share from continuing operations was USD 0.37 compared to USD 0.36 a year ago.
Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Companyâs products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Companyâs Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
NAUTILUS BIOTECHNOLOGY, INC. 
